Amarin Corp Plc\Uk
$5.63B- Market cap
- $5.75B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.33x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: AMRN stock price at premium vs UL $13.69 current versus $1.23 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at UL's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 8, 10:58 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · UL FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.33x
Capital structure 74% equity / 26% debt · EV / Revenue 3.28x · EV / EBITDA 16.56x
UL carries the larger enterprise value at $192.48B against $5.63B; UL trades on the lower EV / Revenue multiple (3.28x vs 26.33x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
UNILEVER PLC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
—
Net debt / EBITDA
Leverage against operating earnings
3.79x
4.53x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$3.94B
Total debt
Interest-bearing obligations outstanding
$177.39M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
PROCTER & GAMBLE Co
AMRN vs PG
COLGATE PALMOLIVE CO
AMRN vs CL
JOHNSON & JOHNSON
AMRN vs JNJ
KIMBERLY CLARK CORP
AMRN vs KMB
CHURCH & DWIGHT CO INC /DE/
AMRN vs CHD
$49.28B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.